Debut Plus

448.5

+5.14 +1.16%

10 Sept 2026

NSE Listed · Pharmaceuticals

Cohance Lifesciences Ltd. (COHANCE)

Volume: 8,07,343Avg Vol 1W: 10,94,909Avg Vol 1M: 11,66,32352W Range:266.71,027
Market Cap₹17,159 Cr
Current Price₹448.5
Previous Close₹443.36
High / Low (52w)₹1,027 / ₹266.7
Volume8,07,343
Avg Vol (1W)10,94,909
Avg Vol (1M)11,66,323
Stock P/E159.61
Book Value₹102.23
Dividend Yield0%
ROE5.05%
ROA102.15%
Revenue (TTM)
Revenue Growth13.91%
Profit Margin496.05%
Total Debt₹6 Cr
Shares Outstanding38 Cr
Face Value₹1
EPS (TTM)₹2.81
P/B4.39
Debt / Equity0.12
50 DMA₹444.47
200 DMA₹422.02
Day change+1.16%
Price Chart
448.5 54.69% · 1Y
10842804.8Cr
2025-09-10
2026-09-10

20-day avg volume: 12.3L shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 37% YoY.
  • Stock trades at a high P/E of 160.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹604 Cr₹676 Cr₹840 Cr₹549 Cr₹556 Cr₹545 Cr₹619 Cr₹422 Cr
EBITDA₹184 Cr₹215 Cr₹187 Cr₹81 Cr₹93 Cr₹55 Cr₹46 Cr₹-36 Cr
Net Profit₹138 Cr₹153 Cr₹120 Cr₹49 Cr₹74 Cr₹37 Cr₹20 Cr₹-24 Cr
EPS
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹2,678 Cr₹769 Cr₹484 Cr₹498 Cr₹482 Cr₹568 Cr₹2,303 Cr₹360 Cr
EBITDA₹699 Cr₹188 Cr₹86 Cr₹126 Cr₹76 Cr₹78 Cr₹274 Cr₹4 Cr
Net Profit₹487 Cr₹123 Cr₹53 Cr₹94 Cr₹47 Cr₹35 Cr₹179 Cr₹1 Cr
EPS12.684.68
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹783 Cr₹1,173 Cr₹1,474 Cr₹1,830 Cr₹1,966 Cr₹2,254 Cr₹5,481 Cr₹5,730 Cr
Total Liabilities₹193 Cr₹328 Cr₹294 Cr₹302 Cr₹231 Cr₹203 Cr₹1,688 Cr₹1,696 Cr
Equity₹590 Cr₹845 Cr₹1,181 Cr₹1,527 Cr₹1,735 Cr₹2,051 Cr₹3,793 Cr₹4,034 Cr
Total Debt
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹83 Cr₹493 Cr₹492 Cr₹514 Cr₹603 Cr₹468 Cr₹849 Cr₹436 Cr
Investing₹-65 Cr₹-413 Cr₹-311 Cr₹-136 Cr₹-195 Cr₹-362 Cr₹-390 Cr₹-255 Cr
Financing₹26 Cr₹7 Cr₹-76 Cr₹-156 Cr₹-242 Cr₹-14 Cr₹-327 Cr₹-165 Cr
Free Cash Flow₹83 Cr₹493 Cr₹492 Cr₹514 Cr₹603 Cr₹468 Cr₹849 Cr₹436 Cr
Shareholding
Promoter 57.49% Institutions 26.59% Public 15.93%
Efficiency & Working Capital
ROCE5.5%
Interest Coverage6.6
Dividend Payout
Debtor Days110 d
Inventory Days90 d
Payable Days46 d
Cash Conversion Cycle154 d
Working Capital Days200 d
Shareholding Details

As of 2026-06-30

Promoter57.5%
FII6.5%
DII20.1%
Institutions26.6%
Public15.9%
Promoter Pledge94.6%
No. of Shareholders99,149
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2024Jun 2024Sept 2024Dec 2024Mar 2025May 2025May 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters50.1%50.1%50.1%50.1%50.1%66.4%66.4%66.4%57.5%57.5%57.5%57.5%
FIIs9.5%9.8%10.7%10.8%11%7.4%7.4%7.2%6.5%6%5.6%6.5%
DIIs17.2%17.4%16.9%16.7%16.6%11%11%11.4%20.8%21.6%21.8%20.1%
Public23.1%22.7%22.3%22.4%22.2%15.2%15.2%15%15.2%14.9%15.1%15.9%
Promoter Pledge0%0%0%0%0%0%0%100%100%100%100%94.6%
No. of Shareholders68,93265,77769,33784,21086,32588,65888,65880,91075,28481,87785,23099,149
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Behryanda LimitedShareholding of Promoter and Promoter Group33.3%12.75 Cr
Jusmirial Holdings LimitedShareholding of Promoter and Promoter Group24.2%9.24 Cr
Dsp Regular Savings FundPublic Shareholding4.3%1.64 Cr
Icic Preduential Health Care And DiaganosticPublic Shareholding4.2%1.60 Cr
Jasub Property Holdings LlpPublic Shareholding3.8%1.47 Cr
Sbi Mnc FundPublic Shareholding3.3%1.27 Cr
Jasti Property And Equity Holdings Private LimitedPublic Shareholding2.5%96,16,009
Hdfc Trustee Company Limited - Hdfc Tax Saver FundPublic Shareholding2.2%82,49,905
Sbi Life Insurance Co. LtdPublic Shareholding1.8%66,99,607
Invesco India Contra FundPublic Shareholding1.7%64,64,885
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Behryanda Limited12.75 Cr100%2026-06-30
Jusmirial Holdings Limited8.04 Cr87.1%2026-06-30
Board of Directors
NameDesignationYear
Vivek SharmaChairman & Exec. Director2025
Vinod PadikkalNon-Exec & Non-Independent Dir2025
K G AnanthakrishnanIndependent Non Exe. Director2025
Matangi GowrishankarIndependent Non Exe. Director2025
Vinod RaoIndependent Non Exe. Director2025
U B Pravin RaoIndependent Non Exe. Director2025
Jaishankar KrishnanIndependent Non Exe. Director2025
Pankaj PatwariNon Executive Director2025
Shweta JalanNon Executive Director2025
KUNDAN KUMAR JHACS / Compliance Officer / Legal Head2025
Himanshu AgarwalWhole Time Director & Chief Financial Officer2025
Segments — Product
SegmentRevenueShare
Manufacturing of Bulk Drugs & Inter₹0 Cr
Segments — Geography
RegionRevenueShare
USA₹495 Cr24.7%
Europe₹712 Cr35.6%
India₹308 Cr15.4%
Rest of the world₹488 Cr24.4%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹13,5343838
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-05Board Meetings
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202520025027
2025000707
202500018018
Insider / Designated-Person Trades

1 recent disclosure(s)

Jusmiral Holdings LimitedDisposal · 3,41,48,000
Substantial Acquisitions (SAST)

6 disclosure(s)

Market07/08/2026 · 28,99,996
Inter-se Transfer23/02/2026 · 77,00,000
Inter-se Transfer18/02/2026 · 70,00,000
Market18/02/2026 · 78,76,948
Release Of Encumbrances18/09/2025 ·
Market18/09/2025 · 3,41,48,000
Company Information
Incorporated2018
ChairmanVivek Sharma
AuditorWalker Chandiok & Co LLP
Investor Email[email protected]
🌐 www.suvenpharm.com

📍 8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search